檢索結果 - Matthew D. Hellmann
- Showing 1 - 20 results of 162
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma 由 Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg
出版 2010Artigo -
11
-
12
-
13
-
14
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas 由 Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon
出版 2015Artigo -
15
PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden 由 Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares
出版 2018Artigo -
16
-
17
-
18
-
19
-
20
Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders 由 Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad
出版 2018Artigo
相關主題
Medicine
Internal medicine
Cancer
Oncology
Immunotherapy
Lung cancer
Biology
Cancer research
Immunology
Immune system
Genetics
Gene
Receptor
Nivolumab
Blockade
Adverse effect
Immune checkpoint
Pathology
Clinical trial
Chemotherapy
Lung
Gastroenterology
Mutation
Pembrolizumab
PD-L1
Computational biology
Confidence interval
Cohort
Ipilimumab
T cell